Developmental and reproductive toxicity (DART) studies are crucial in identifying risks to human health and assessing the overall safety of chemicals and other substances present in the environment, consumer products, Read more about Developmental and Reproductive Toxicity (DART) Studies[…]
If you were unable to attend the AGRO Division Lunch & Learn webinar, the full recording is now available to watch below. During this session, Dr. Adela Ben-Yakar and Dr. Read more about Webinar: AI-Accelerated Developmental and Reproductive Toxicity Assessment with vivoDART™[…]
Developmental toxicity (DevTox) occurs when a chemical or substance disrupts an organism’s normal growth and developmental processes. The mechanisms underlying developmental toxicity may include structural malformations, molecular growth pathway interference, Read more about A Predictive NAM for Developmental Toxicity Testing[…]
On April 10, 2025, the FDA announced a major policy shift: creating a roadmap outlining a strategic approach to reduce animal testing in preclinical safety studies. This transition prioritizes New Approach Read more about The FDA’s Shift from Animal Testing: Role of Small Model Organisms as NAMs[…]
They may be tiny, but Caenorhabditis elegans (C. elegans) are titans in the world of science. Named for their elegant, wave-like movements, these microscopic nematode worms have quietly powered some Read more about Tiny Titans of Science: The Nobel-Worthy Science of C. elegans[…]
Caenorhabditis elegans (C. elegans), a tiny transparent roundworm, is one of the most widely used model organisms in scientific research. First introduced to the laboratory by Sydney Brenner in 1965, Read more about Why C. elegans Is a Powerful Model Organism in Biomedical Research[…]
The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA, a small non-coding RNA molecule that plays a crucial Read more about C. elegans scientists awarded 2014 Nobel Prize in Medicine for their pioneering work discovering microRNA[…]
vivoVerse is excited to announce it has been awarded a Phase I SBIR grant from the National Institute of Environmental Health Sciences (NIEHS) for the continued development of the company’s Read more about vivoVerse awarded NIH/NIEHS grant to develop novel approaches for developmental neurotoxicity testing[…]
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $1.83M Phase II SBIR grant from the National Institute of Environmental Health Sciences (NIEHS) for the Read more about vivoVerse awarded SBIR Phase II grant from the NIEHS[…]
Model organisms are non-human species that we use to study biological phenomena that are recapitulated in humans. Lab mice (Mus musculus), fruit flies (Drosophila melanogaster), and the bacterium E. coli Read more about Nobel Nematode – A History of C. elegans as a Model Organism[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)